oxaliplatin / Generic mfg. 
Welcome,         Profile    Billing    Logout  

1709 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT02047474: Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

Active, not recruiting
2
46
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, therapeutic conventional surgery, laboratory biomarker analysis
Yale University, National Cancer Institute (NCI)
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
02/26
12/26
NCT05062317: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases

Recruiting
2
120
US
Leucovorin, Citrovorum, Wellcovorin®, 5-FLUOROURACIL, Oxaliplatin, Eloxatin, Irinotecan, Capecitabine, Xeloda, Bevacizumab, Avastin™, Anti-VEGF monoclonal antibody, rhuMAb-VEGF
M.D. Anderson Cancer Center
Liver Metastases
02/26
02/26
NCT05729646: Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Recruiting
2
90
RoW
Toripalimab, Oxaliplatin, S1
Yu jiren
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency
02/26
02/29
NCT05929885: Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

Recruiting
2
50
RoW
Low Dose OXIRI (LD-OXIRI)
National Cancer Centre, Singapore, National Medical Research Council (NMRC), Singapore
Metastatic Pancreatic Cancer
02/26
02/26
NCT05000554: The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer

Recruiting
2
30
RoW
Neoadjuvant Therapy
The First Hospital of Jilin University
Gastric Cancer
03/26
06/26
NCT05720559: Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

Not yet recruiting
2
100
NA
Oxaliplatin, S1, Cetuximab, Metronidazole, Vitamin A, Folic acid, Capecitabine
Liaoning Tumor Hospital & Institute
Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer
03/26
09/26
NCT05651594: Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Recruiting
2
40
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Propranolol Hydrochloride, Inderal, Innopran XL, Questionnaire Administration
Roswell Park Cancer Institute, United States Department of Defense
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Esophageal Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
03/26
03/26
AMBITION, NCT05939661: A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer

Recruiting
2
45
Japan
Radiation, Chemotherapy, Surgery
Osaka University
Rectal Cancer
03/26
03/30
NCT04162665: Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

Recruiting
2
36
US, RoW
Adaptive short course radiation therapy, Standard of care chemotherapy regimen
Washington University School of Medicine, Viewray Inc.
Gastric Adenocarcinoma
04/26
04/27
NCT05872685: Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)

Recruiting
2
314
RoW
S1, Oxaliplatin, Serplulimab, Placebo
Yu jiren
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair
04/26
04/29
NCT05851924: A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
2
60
US
NALIRIFOX, AD-XRT and Capecitabine
Memorial Sloan Kettering Cancer Center, Ipsen, Pancreatic Cancer Research Fund
Pancreatic Ductal Adenocarcinoma
05/26
05/26
SCOTI, NCT05806931: Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

Recruiting
2
50
US
TAS-102, oxaliplatin, irinotecan with bevacizumab
Rutgers, The State University of New Jersey
Colon Cancer, Rectal Cancer
05/26
05/27
PHOX, NCT06078709: Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

Recruiting
2
99
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Endoscopic Ultrasound, endosonography, EUS, Esophagogastroduodenoscopy, EGD, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Survey Administration
Mayo Clinic, National Cancer Institute (NCI)
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
05/26
11/26
PANCREAS, NCT04683315: PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Recruiting
2
87
US
mFOLFIRINOX Treatment Regimen, Fluorouracil, Folinic acid, Camptosar, Eloxatin, Gemcitabine/Nab-paclitaxel Treatment Regimen, Gemzar, Abraxane, Chemoradiation
Medical College of Wisconsin
Pancreatic Cancer
06/26
06/27
NCT04443543: An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer

Not yet recruiting
2
222
RoW
Capecitabine (Xeloda) Pharmacogenetic Test Reagents, irinotecan, IMRT, Oxaliplatin, 5Fluorouracil, Tislelizumab
Fudan University
Rectal Cancer
06/26
12/26
NCT05864105: PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma

Recruiting
2
35
RoW
PM8002, FOLFOX regimen
Biotheus Inc.
Hepatocellular Carcinoma
06/26
06/26
NCT05970627: Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Not yet recruiting
2
30
RoW
Toripalimab, Oxaliplatin, S1
Yu jiren
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma
07/26
07/29
NCT05671822: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer

Recruiting
2
156
RoW
SHR-A1811；SHR-1701；capecitabine；oxaliplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
07/26
07/26
NCT03322995: Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

Recruiting
2
125
US
First-line Chemotherapy, Fluorouracil, Folinic acid, Camptosar, Eloxatin, Second-line Chemotherapy, Gemzar, Chemoradiation
Medical College of Wisconsin
Pancreatic Cancer
08/26
08/27
NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Recruiting
2
70
Europe
Ompenaclid (RGX-202), Placebo, Bevacizumab, FOLFIRI regimen
Inspirna, Inc.
Colorectal Cancer, Metastatic Colon Cancer
08/26
08/28
NCT05870800: Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer

Not yet recruiting
2
30
US
Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Neoadjuvant Chemoimmunotherapy, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, mFOLFOX6, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2, CAPEOX
Baylor College of Medicine, Genentech, Inc.
Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
09/26
01/28
NCT06094868: Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

Not yet recruiting
2
45
NA
Fruquintinib, Sintilimab, Oxaliplatin, Capecitabine
Second Affiliated Hospital of Nanchang University
Gastric Cancer
10/26
10/26
B2019-149, NCT04304209: Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Active, not recruiting
2
195
RoW
Oxaliplatin, Capecitabine, Sintilimab, radiotherapy, total mesorectal excision, Watch and wait
Sun Yat-sen University
Colorectal Cancer Stage II, Colorectal Cancer Stage III
10/26
10/26
NCT06106308: Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Recruiting
2
90
US
Onvansertib, FOLFIRI, Bevacizumab, FOLFOX
Cardiff Oncology, Pfizer
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
11/26
01/27
ANTONIO, NCT05118724: Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin

Recruiting
2
80
Europe
Atezolizumab, Tecentriq
AIO-Studien-gGmbH, Roche Pharma AG, Immodulon Therapeutics Ltd
Colorectal Cancer
11/26
11/26
ChiCTR2200055702: An Open Label, Single-centre, Pilot study of Olaparib combo Durvalumab as Sequential Treatment, following Adjuvant modified FOLFIRINOX in HRR Mutated Resected Pancreatic Adenocarcinoma Patients

Recruiting
2
30
China
Olaparib combo Durvalumab
Fudan University Shanghai Cancer Center ; Fudan University Shanghai Cancer Center, Study fee and study drug were provided by AZ
Resected Pancreatic Adenocarcinoma Patients
 
 
NCT06070740: First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma

Recruiting
2
22
RoW
Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
Peking Union Medical College Hospital
Gastrointestinal Neuroendocrine Carcinoma
11/26
12/26
NCT06124378: Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

Recruiting
2
60
RoW
Tislelizumab, Tevimbra, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Colectomy, Surgery
First Affiliated Hospital of Guangxi Medical University
Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
11/26
11/26
NCT03825861: Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer

Recruiting
2
27
RoW
FOLFIRINOX
Instituto do Cancer do Estado de São Paulo
Gastric Cancer
12/26
12/26
NCT03776487: Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Active, not recruiting
2
32
US
Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Localized Gastric Carcinoma, Localized Gastroesophageal Junction Adenocarcinoma, Pathologic Stage 0 Gastric Cancer AJCC v8, Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage I Gastric Cancer AJCC v8, Pathologic Stage IA Gastric Cancer AJCC v8, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
12/26
12/26
NCT04566380: ONO-4538 Phase II Rollover Study (ONO-4538-98)

Recruiting
2
59
Japan, RoW
ONO-4538, oxaliplatin, S-1, capecitabine, bevacizumab, temozolomide
Ono Pharmaceutical Co. Ltd
Pan-tumor
12/26
12/26
NCT05727163: FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Recruiting
2
194
RoW
Dexamethasone, Anisodamine, 654-2, Oxaliplatin, Leucovorin, Fluorouracil, FU, Irinotecan, Bevacizumab
Sun Yat-sen University
Colorectal Cancer Metastatic
12/26
12/26
HERCKER-01, NCT05985707: KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Not yet recruiting
2
80
RoW
KN026, KN046, XELOX
Peking University Cancer Hospital & Institute
HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer
12/26
12/26
NCT05998122: Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study

Not yet recruiting
2
45
RoW
nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
The First Hospital of Jilin University
Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1
12/26
12/28
NCT05985109: KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

Recruiting
2
98
RoW
KN046, regorafenib
Peking University Cancer Hospital & Institute
Colorectal Cancer
12/26
12/26
ChiCTR2200056870: An open, multicenter, single-arm, phase II study evaluating triplimumab injection (JS001) combined with chemotherapy for neoadjuvant treatment of gastric/gastroesophageal junction cancer

Not yet recruiting
2
40
China
Toripalimab injection (JS001) combined with capecitabine and oxaliplatin
Guangdong Provincial People's Hospital ; Guangdong Provincial People's Hospital, Tririplizumab injection (JS001) was provided free of charge by Shanghai Junshi Biomedical Technology Co., LTD.
gastric/gastroesophageal junction carcinoma
 
 
KEYVIBE-005, NCT05007106 / 2021-001009-56: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)

Recruiting
2
610
Europe, Canada, Japan, US, RoW
Pembrolizumab/Vibostolimab Co-Formulation, MK-7684A, Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, Lenvima, E7080, MK-7902, 5-Fluorouracil, 5-FU, Fluracil, Cisplatin, Platinol, cis Platinum, Paclitaxel, Taxol, Abraxane, Anzatax, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
02/27
02/27
OPTIMISE, NCT04680260: OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer

Recruiting
2
350
Europe
Standard of care, Circulating tumor DNA guided treatment approach
Karen-Lise Garm Spindler, Vejle Hospital, Zealand University Hospital
Colorectal Cancer, Metastatic Cancer
03/27
03/30
GABRINOX2, NCT05065801: Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

Recruiting
2
162
Europe
GABRINOX, FOLFIRINOX
Institut du Cancer de Montpellier - Val d'Aurelle
Metastatic Pancreatic Cancer
03/27
11/27
AIRPanc, NCT06048484: Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Recruiting
2
60
US
Stereotactic body radiotherapy (SBRT), Zimberelimab, AB122, Quemliclustat, AB680, Etrumadenant, AB928, Modified FOLFIRINOX, mFOLFIRINOX
Gulam Manji, Arcus Biosciences, Inc.
Pancreatic Ductal Adenocarcinoma
04/27
04/27
AK104-IIT-13, NCT05794750: Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（）

Not yet recruiting
2
50
NA
AK104 injection, Immunotherapy, TME surgery, Surgery, Capecitabine, Chemotherapy drug, Oxaliplatin
JIN JING
Locally Advanced Rectal Cancer
04/27
04/27
NCT05228431: Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer

Recruiting
2
121
RoW
XELOX, Capecitabine monotherapy, Radiation
Zhen-Hai Lu
Advanced Rectal Cancer
05/27
05/28
DANTE, NCT03421288 / 2017-001979-23: Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

Recruiting
2
674
Europe
Atezolizumab, TECENTRIQ, 5-Fluorouracil, 5-FU, Calciumfolinat, Leucovorin, Oxaliplatin, ELOXATIN, Docetaxel, TAXOTERE
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/27
12/27
NCT05494697: Ampligen Compared to No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Recruiting
2
90
US
Rintatolimod, Ampligen, poly I : poly C12U
AIM ImmunoTech Inc., Amarex Clinical Research
Pancreatic Cancer
06/27
07/27
NCT03977233: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting
2
45
US
Oxaliplatin, Eloxatin, Leucovorin, folinic acid, Irinotecan Hydrochloride, Camptosar, 5-FU, Adrucil
UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
07/27
01/30
HLPDTLT, NCT05475613: Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation

Recruiting
2
59
RoW
Downstaging procedures containing immunotherapy, Liver transplantation
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Liver Transplantation, Hepatocellular Carcinoma
08/27
08/28
MRIMR-1, NCT05359393: A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis

Not yet recruiting
2
52
RoW
a combination therapy including tislelizumab, preoperative radiotherapy combined with immunotherapy and chemotherapy
Fudan University
Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis, Microsatellite Stable Colorectal Carcinoma
09/27
09/27
NCT05504720: Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

Active, not recruiting
2
31
Europe
Pembrolizumab, Keytruda, Trastuzumab, Ontruzant, FLOT
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Merck Sharp & Dohme LLC, Organon Healthcare GmbH
Esophagogastric Adenocarcinoma
10/27
12/27
NCT05836584: Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Recruiting
2
240
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Echocardiography, EC, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Lymphadenectomy, excision of the lymph node, Lymph Node Dissection, Lymph Node Excision, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
National Cancer Institute (NCI)
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/27
10/27
NCT03391843: Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer

Active, not recruiting
2
100
RoW
FOLFOXIRI+Cetuximab regimen, CPT 11,CAMPTO，Eloxatin，Xelod，Eloxatin,Erbitux
RenJi Hospital
Rectal Cancer Stage III
12/27
12/27
NCT05286814: M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

Recruiting
2
48
US
Floxuridine, 5-Fluorouracil, Irinotecan, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Oxaliplatin, Leucovorin, M9241, Gemcitabine, Dexamethasone
National Cancer Institute (NCI)
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Colorectal Cancer, Colorectal Neoplasms, Cholangiocarcinoma, Intrahepatic Bile Duct Cancer, Bile Duct Cancer, Bile Duct Neoplasms
12/27
12/28
STEREOPAC, NCT05083247: Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Recruiting
2
256
Europe
mFOLFIRINOX or Gemcitabine nab-paclitaxel, mFFX or Gem/Nab-p, Isotoxic High-Dose (iHD)-SBRT, Surgery
Erasme University Hospital, Jules Bordet Institute, Belgian Group of Digestive Oncology, University Hospital St Luc, Brussels
Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
12/27
12/30
TRACE-LE, NCT05969847: Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer

Not yet recruiting
2
72
RoW
split-course hypofraction radiotherapy, hypofraction radiotherapy, CAPOX, Capecitabine+Oxaliplatin, Envafolimab, KN035, Local excision
池畔
Rectal Cancer
12/27
12/27
NCT04643366: Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

Recruiting
2
54
US
Chemotherapy, Radiation Therapy
Virginia Commonwealth University
Rectal Cancer
01/28
01/33
NCT06109467: Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Recruiting
2
36
US
Neratinib, NERLYNX, Trastuzumab, Herceptin, Oxaliplatin, Eloxatin, 5-Fluorouracil + leucovorin, Pembrolizumab, Keytruda
H. Lee Moffitt Cancer Center and Research Institute, Puma Biotechnology, Inc., National Comprehensive Cancer Network
GastroEsophageal Cancer, Gastric Cancer
04/28
04/28
ChiCTR2300070798: Conversion therapy of Sintilimab combined with Lenvatinib and XELOX (oxaliplatin and capecitabine) chemotherapy in primary unresectable gastric cancer

Not yet recruiting
2
34
 
Sintilimab combined with Lenvatinib and XELOX (oxaliplatin and capecitabine) chemotherapy
JiangSu province hospital; JiangSu province hospital, self-financing
gastric cancer
 
 
SIRIUS, NCT05375708: Systemic Therapy in Combination With Stereotactic Radiotherapy in Patients With Metastatic Colorectal Cancer up to 10 Metastatic Sites

Not yet recruiting
2
93
Europe
Stereotactic body radiation therapy (SBRT), Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
UMC Utrecht
Metastatic Colorectal Cancer, Oligometastatic Disease
06/28
06/28
NCT05825066: Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Recruiting
2
64
US
Nab paclitaxel, Gemcitabine, Radiological Assessments, mFOLFIRINOX
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
07/28
07/29
NCT05526079: Watchful Waiting for Complete Responders to Therapy in Rectal Cancer

Recruiting
2
30
US
Watchfuf waiting
Ascension South East Michigan
Rectal Cancer
07/28
07/29
TOGAR, NCT05567835: A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer

Recruiting
2
50
US
Fluorouracil, 5-FU, Leucovorin, LV, Oxaliplatin, Eloxatin, Docetaxel, Taxotere, GSCF
Baylor College of Medicine
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/28
01/29
FOLFIRINOX3 P, NCT05988814: Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

Recruiting
2
90
Europe
FOLFIRINOX treatment
Centre Georges Francois Leclerc
Metastatic Pancreatic Cancer
07/29
07/29
TASLARC, NCT05965531: Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy

Not yet recruiting
2
65
RoW
Trifluridine/Tipiracil, TAS-102, intensity-modulated radiotherapy
Sun Yat-sen University
Rectal Cancer
12/28
12/28
IMCODE003, NCT05968326: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma

Recruiting
2
260
Europe, Canada, US
Autogene cevumeran, Atezolizumab, Tecentriq, mFOLFIRINOX
Genentech, Inc., BioNTech SE
Adenocarcinoma, Pancreatic Ductal
12/29
12/29
NCT03366155: Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

Recruiting
2
40
US
Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex, Oxaliplatin, 5FU, Irinotecan, HAIP installation, cetuximab, Medtronic SynchroMed II Pump
National Cancer Institute (NCI)
Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases, Colorectal Carcinoma
12/29
12/30
NCT05564377: Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Recruiting
2
2900
US
Alpelisib, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Ipatasertib, GDC-0068, RG-7440, Leucovorin, Folinic acid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mutation Carrier Screening, Neratinib Maleate, 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1), HKI-272 Maleate, NERATINIB MALEATE ANHYDROUS, Nerlynx, Nilotinib Hydrochloride Monohydrate, AMN107, Nilotinib Monohydrochloride Monohydrate, Tasigna, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Vectibix, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate, Sotorasib, AMG 510, AMG-510, AMG510, Lumakras, Lumykras
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
07/30
07/30
CENDIFOX, NCT05121038: CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab

Recruiting
1b/2a
50
US
CEND-1, Panitumumab, Folfirinox, Oxaliplatin,Leucovorin,Irinotecan,Fluorouracil
Anup Kasi, Cend Therapeutics Inc.
Colon Cancer, Pancreas Cancer, Digestive Cancer
09/23
09/25
YY-20394-008, NCT04500561: YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Not yet recruiting
1b/2
28
NA
YY-20394, Gemcitabine, Oxaliplatin
Shanghai YingLi Pharmaceutical Co. Ltd.
Diffuse Large B Cell Lymphoma
10/21
12/21
QUILT-3.071, NCT03563157: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Active, not recruiting
1b/2
332
US
Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
ImmunityBio, Inc.
Colorectal Cancer Metastatic, mCRC
12/22
12/22
SCORPIO, NCT05986227: The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):

Not yet recruiting
1b/2
126
NA
toripalimab FOLFOX
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastroesophageal Adenocarcinoma
07/25
07/26
NCT05990543: Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

Not yet recruiting
1b/2
59
NA
Nelmastobart and Capecitabine
Korea University Anam Hospital
Recurrent or Metastatic Colorectal Cancer
10/25
03/26
ACTRN12617001268336: Direct Isolation Chemotherapy to Supplement Systemic Intravenous Chemotherapy for those with Liver Metastases from Colorectal Cancer

Recruiting
1/2
95
 
AllVascular Pty Ltd, NSW Health Medical Device Fund
Liver Cancer
 
 
ACTRN12606000007538: Phase 1/2 study of SIR-Spheres plus systemic chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin in patients with liver metastases from colorectal carcinoma

Active, not recruiting
1/2
20
 
Sirtex Medical Limited, Sirtex Medical Limited
Unresectable liver metastases from colorectal carcinoma
 
 
ACTRN12616001112459: Study comparing the Efficacy and Safety of FOLFIRINOX ( Fluoropyrimidine, Oxaliplatin and Irinotecan) as Chemotherapy regimen For Resectable Gastric Or Gastroesophageal Junction Cancer to ECF (Cisplatin, Epirubicin and Fluoropyrimidine) as chemotherapy regimen which is the standard treatment

Recruiting
1/2
202
 
Royal Adelaide Hospital, Royal adelaide hospital
Resectable gastroesophageal junction adenocarcinoma , Resectable gastric adenocarcinoma.
 
 
ChiCTR-ONC-12001907: The reverse effect of Asipirin on oxaliplatin-resistant patients

Completed
1/2
30
 
Aspirin + FOLFOX4
The Fourth Affiliated Hospital, Soochow University; Department of health, Jiangsu Province, Zhejiang Kanglaite Group Co., Ltd
Advanced chemoresistant colorectal cancer
 
 
2009-010093-38: Multi-institutional Phase I/II Study: Neoadjuvant chemoradiation with 5-FU (or capecitabine) and oxaliplatin combined with deep regional hyperthermia in locally advanced or recurrent rectal cancer

Ongoing
1/2
110
Europe
Capecitabine, Oxaliplatin, Solution for infusion, Film-coated tablet, Concentrate for solution for infusion
Dekan of the Medical Faculty of the University Erlangen-Nuremberg; Prof. Dr. Dr. h. c. Jürgen Schüttler, Strahlenklinik Erlangen
Locally advanced primary or locally recurrent rectal cancer, Locally advanced primary or locally recurrent rectal cancer, Diseases [C] - Digestive System Diseases [C06]
 
 
NCT01671202: LY2090314 With Gemcitabine Hydrochloride or FOLFOX Combination Chemotherapy in Treating Patients With Untreated, Metastatic Pancreatic Cancer

Not yet recruiting
1/2
40
US
LY2090314, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, pharmacological study, pharmacological studies, laboratory biomarker analysis
Mayo Clinic, National Cancer Institute (NCI)
Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
06/13
 
2012-003678-13: Phase I-II trial of gemcitabine plus nab-paclitaxel (GemBrax) followed by FOLFIRINOX as first-line treatment of patients with metastatic pancreatic adenocarcinoma

Not yet recruiting
1/2
118
Europe
Powder for suspension for injection, Powder for solution for infusion, Solution for infusion, Solution for injection, ABRAXANE, GEMCITABINE, OXALIPATINE, CAMPTO, FOLINATE DE CALCIUM, FLUOROURACILE
Institut Régional de Cancerologie de Montpellier - Val d’Aurelle, Laboratory CELGENE
metastatic pancreatic adenocarcinoma, Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
2013-004385-34: Activity of Regorafenib in combination with modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in patients with advanced Biliary Tract Cancer (BTC): A Phase Ib-II trial

Not yet recruiting
1/2
87
Europe
Coated tablet, Powder for solution for infusion, STIVARGA, GEMCITABINE, OXALIPLATINE
Institut régional du Cancer - Montpellier - Val d'Aurelle, Institut régional du Cancer - Montpellier - Val d'Aurelle
advanced Biliary Tract Cancer, Biliary Cancer, Diseases [C] - Cancer [C04]
 
 
NCT01714453: NPC-1C With Gemcitabine for Advanced Pancreatic Cancer

Not yet recruiting
1/2
18
US
NPC-1C Antibody, Gemcitabine
National Cancer Institute (NCI), Precision Biologics Oncology, Inc.
Metastatic Pancreatic Neoplasms
10/14
10/14
2009-011041-12: Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité.

Ongoing
1/2
64
Europe
Yondelis, Oxaliplatin, ET-743, Yondelis 0.25 mg and 1.0 mg, Yondelis 0.25 mg and 1.0 mg
Pharma Mar S.A.
Pretreated Advanced Ovarian Cancer
 
 
2009-009928-37: Phase 1/2 Studie:CONKO-008Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie

Ongoing
1/2
95
Europe
Lapatinib, GW572016, Tyverb, MEDOXA, Fluorouracil-GRY, Calciumfolinat-GRY, Tyverb, MEDOXA, Fluorouracil-GRY, Calciumfolinat-GRY
Charite Universitätsmedizin Berlin
Pancreatic cancer patients who failed first line therapy with gemcitabine
 
 
ChiCTR-IIR-16007947: The Study of Neoadjuvant Sandwich Treatment with XELOX Induction Chemotherapy and 5-Fu based Radiotherapy for Locally Advanced Rectal Cancer

Recruiting
1/2
80
 
5-Fu based Radiotherapy ;XELOX induction chemotherapy and 5-Fu based radiotherapy
Shanghai ChangZheng Hospital; Shanghai ChangZheng Hospital, self-collected funds
Rectal Cancer
 
 
ChiCTR-OIC-16007966: Oxaliplatin-hepatic arterial infusion chemotherapy (OXA-HAIC) plus Tiji'ao for treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus

Recruiting
1/2
25
 
OXA-HAIC plus Tiji'ao
The Afiliated Tumor Hospital of Xinjiang Medical University; The Afiliated Tumor Hospital of Xinjiang Medical University, no
Hepatocellular carcinoma
 
 
SORT, ChiCTR-IPR-14005682: Clinical observation and efficacy predictors of the combined use of S1 and oxaliplatin in treating metastatic triple-negative breast cancer

Recruiting
1/2
60
 
Oxaliplatin 130mg/m2 D1, S-1 50mg/m2, b.i.d. D1-14, repeated every 3 weeks ;Gemcitabine 1000mg/m2 Vinorelbine 25mg/m2 D1, D8, repeated every 3 weeks
Breast Disease Center, ChongQing Tumer Hospital; None, Chongqing Health and Family Planning Commission
metastatic triple-negative breast cancer
 
 
2018-003541-42: Safety, tolerability and efficacy of regorafenib in combination with FOLFIRINOX in patients with RAS-mutated metastatic colorectal cancer: a dose-escalation, phase I/II trial - FOLFIRINOX-R

Not yet recruiting
1/2
87
Europe
REGORAFENIB, Oxaliplatine, IRINOTECAN, ELVORINE, FLUOROURACILE, BAY 73-4506, Coated tablet, Powder for solution for infusion, Solution for injection, STIVARGA (Régorafénib), OXALIPLATINE, IRINOTECAN, ELVORINE, FLUOROURACILE
Institut régional du Cancer de Montpellier
RAS-mutated metastatic colorectal cancer, RAS-mutated metastatic colorectal cancer, Diseases [C] - Cancer [C04]
 
 
NCT01959139: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Completed
1/2
126
US
PEGPH20, Pegylated Recombinant Human Hyaluronidase, Oxaliplatin, Eloxatin, NSC-266046, Leucovorin, leucovorin calcium, Irinotecan, CPT-11, NSC-616348, 5-fluorouracil, 5-FU, Adrucil, NSC-19893
SWOG Cancer Research Network, National Cancer Institute (NCI), Halozyme Therapeutics
Metastatic Pancreatic Adenocarcinoma
04/19
11/23
ChiCTR-OIC-17012827: S-1/irinotecan/oxaliplatin regimen in patients with with locally advanced or metastatic pancreatic adenocarcinoma

Recruiting
1/2
30
 
SOXIRI chemotherapy
Fudan University Affiliated Huadong Hospital; Fudan University Affiliated Huadong Hospital, Fudan University Affiliated Huadong Hospital
Pancreatic Adenocarcinoma
 
 
NCT03641183: Neoadjuvant Therapy Followed by Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer

Recruiting
1/2
30
US
FOLFIRINOX Drugs, 5-FU (Fluorouracil), Folinic Acid, Oxaliplatin, Irinotecan, Gemcitabine-nab Paclitaxel, Abraxane
University of Alabama at Birmingham
Pancreas Cancer
03/20
03/20
2019-003727-38: MEN1611 in Colorectal Cancer

Ongoing
1/2
44
Europe
MEN1611, Cetuximab, MEN1611, Cetuximab, Capsule, Solution for solution for infusion, Erbitux 5 mg/mL solution for infusion
Menarini Ricerche S.p.A., MENARINI RICERCHE SPA, Menarini Ricerche S.p.A.
PIK3CA mutated colorectal cancer, PIK3CA mutated colorectal cancer, Diseases [C] - Cancer [C04]
 
 
2019-004483-22: A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or in combination with other agents in patients with HER2- expressing Gastric Cancer

Not yet recruiting
1/2
357
Europe
Trastuzumab Deruxtecan, Durvalumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Trastuzumab, Cisplatin, Pembrolizumab, Volrustomig, DS-8201a, MEDI4736, MEDI5752, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Keytruda 25 mg/mL concentrate for solution for infusion
AstraZeneca AB, ASTRAZENECA AB, AstraZenecaAB, AstraZeneca AB
Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer, Patients with HER2-expressing gastric, GEJ and esophageal cancer, Diseases [C] - Cancer [C04]
 
 
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
NCT04558684: Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer

Suspended
1/2
30
RoW
Chemotherapy, Immunotherapy, IMRT
Wuhan Union Hospital, China
Rectal Cancer, Radiotherapy, Immunotherapy, Organ Preservation
09/20
12/23
NCT04231552: Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer

Active, not recruiting
1/2
30
RoW
Camrelizumab, Radiotherapy with CAPOX+ Camrelizumab following surgical therapy
Wuhan Union Hospital, China
Rectal Cancer, Radiotherapy, Immunotherapy
09/20
09/23
NCT04380103: A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer

Recruiting
1/2
106
RoW
XELOXIRI/Bevacizumab, Irinotecan, Oxaliplatin, Capecitabine, Bevacizumab
Chinese Academy of Medical Sciences
Metastatic Cancer, Colorectal Cancer, Colorectal Adenocarcinoma
12/20
09/22
2020-005182-14: A clinical study investigating the safety and effect of a potential new therapy mitazalimab in combination with standard chemotherapy treatment in patients with pancreatic cancer

Not yet recruiting
1/2
80
Europe
mitazalimab, Oxaliplatin, Leucovorin, Irinotecan, Flurouracil, Gemcitabine, Abraxane, Eloxatine, Calcium Folinate Zentiva, Campto, Flurouracil Teva, Gemcitabine Accord, Abraxane, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Solution for injection/infusion, Powder for solution for injection/infusion
Alligator Bioscience AB, Alligator Bioscience AB
Metastatic Pancreatic Ductal Adenocarcinoma adénocarcinome canalaire pancréatique en phase métastatique, Pancreatic Cancer Cancer du pancréas, Diseases [C] - Cancer [C04]
 
 
NCT02730546: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

Completed
1/2
31
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, RADIATION, Radiotherapeutics, radiotherapy, RT, Therapy, Radiation, Therapeutic Conventional Surgery
Mayo Clinic, National Cancer Institute (NCI)
Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7, Stage IIB Gastric Cancer AJCC v7, Stage IIIA Gastric Cancer AJCC v7, Stage IIIB Gastric Cancer AJCC v7
07/21
10/23
2018-000257-45: A phase Ib/II single-arm study evaluating the safety and efficacy ofcombined immunotherapy with mFOLFOX6, bevacizumab and atezolizumabin advanced-stage biliary cancer Eine einarmige Phase Ib/II Studie zur Untersuchung der Sicherheit und Wirksamkeit einer kombinierten Immuntherapie mit mFOLFOX6, Bevacizumab und Atezolizumab bei fortgeschrittenem Gallengangskarzinom

Not yet recruiting
1/2
35
Europe
Atezolizumab, Bevacizumab, Concentrate for solution for infusion, Tecentriq, Avastin
University Hospital Essen, F. Hoffmann-La Roche Ltd
advanced biliary tract cancer (BTC), advanced biliary tract cancer (BTC), Diseases [C] - Cancer [C04]
 
 
2020-002791-13: A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer

Not yet recruiting
1/2
144
Europe
ABTL0812, ABTL0812, Oral solution
Ability Pharmaceuticals, SL, Ability Pharmaceuticals, SL
Metastatic pancreatic cancer, Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
NCT02671435 / 2016-000662-38: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Hourglass Jan 2021 - Dec 2022 : From trial in combination with monalizumab for solid tumors
Hourglass Jan 2021 - Dec 2021 : Data from P2 expansion cohort 3 of P1/2 trial in combination with monalizumab and cetuximab for SCCHN
Checkmark Combination trial with monalizumab at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: Combination trial with monalizumab at ASCO 2018 [screenshot]
Checkmark Combination study with NKG2A
More
Active, not recruiting
1/2
383
Europe, Canada, US, RoW
Monalizumab, Durvalumab, Cetuximab, mFOLFOX6, Bevacizumab
MedImmune LLC
Advanced Solid Tumors
10/21
09/24
FOLFIRINOX-R, NCT03828799: Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer

Active, not recruiting
1/2
13
Europe
Folfirinox + regorrafenib
Institut du Cancer de Montpellier - Val d'Aurelle
Metastatic Colorectal Cancer
12/21
11/24
 

Download Options